ExoPet™ — veterinary-first EV programs for aging dogs and cats
ExoPet™ is TONGNIAN's companion-animal line: joint, skin, and oral-wellness programs for aging dogs and cats, built veterinary-channel first — clinics and veterinary distributors before consumer shelves. Programs use the same characterized EV material chain as the human lines (species-appropriate documentation), produced on the fully enclosed micro-batch platform with batch COAs on every shipment.
Who this line serves
- Veterinary clinics — in-clinic joint and skin programs administered or supervised by veterinarians.
- Veterinary distributors — regional channels building regenerative-wellness portfolios for clinic networks.
- Pet-parent retail (later phase) — oral-wellness formats that follow once clinic programs establish the category.
Line programs
| Program | Population | Dosage form | Status |
|---|---|---|---|
| Joint program (dogs, cats) | Aging pets with mobility stiffness | Clinic-administered injection course (sample) | Program design stage |
| Skin-recovery comfort gel | Post-procedure and skin-stress cases | Topical gel, 30 mL (sample) | Pilot-ready |
| Oral wellness supplement | Senior dogs and cats | Palatable powder/topper, 30-day jar (sample) | Format development |
| Equine exploration | Sport-horse programs | Program scoping with partners | Long-range |
How the line rolls out
- Single-category entry, then platform — one flagship program per clinic first (skin comfort), then joint and oral programs from the same material chain.
- Veterinary-first channel — clinic education and documentation before any consumer marketing.
- Species-appropriate documentation — the human-line material dossier, adapted to each market's veterinary rules.
- Documented batches — batch COA with every shipment; characterization baseline shared with the human material platform.
Specs & characterization
| Item | Value |
|---|---|
| EV system | Characterized EV base (species-appropriate documentation) |
| Vesicle size (NTA) | 80–150 nm across current programs (sample) |
| Formats | Clinic injection courses, topical gels, oral toppers (sample configurations) |
| QC panel | NTA, TEM, endotoxin (LAL), sterility/microbial limits per format; batch COA |
| Storage | Gel 2–8 °C (sample); toppers cool-dry; injectables per cold-chain spec |
| Compliance status | Material chain: FDA DMF Type II 044197 reference; veterinary regulatory route per destination market |
| Typical program | Clinic pilots by program scope; production from 2,000 units · standard lead 15 workdays |
Quality & compliance
- Veterinary-channel discipline — in-clinic programs positioned for professional administration; no consumer therapeutic claims.
- Material chain — the same DMF/INCI-documented EV platform as the human lines, adapted per market's veterinary rules.
- Closed line — production on the fully enclosed 0.5–5 L micro-batch platform.
- Category whitespace — veterinary EV programs are an early, open category in most markets.
Clinic-channel precedent: US veterinary regenerative programs have validated the clinic-first model for pet care. Context only — not a product claim.
Work with this line: veterinary groups and distributors, start with "Animal health" selected in the quote form.
Customize ExoPet™ dosage forms and skin feel for your brand.
Share your brand stage and target category, and we’ll return sample specs, an MOQ framework, and characterization samples (typical: sample kits in 3–5 days); to review the full-line design first, head to Knowledge · Solutions.